Amgen And AstraZeneca Announce Positive Results From Second Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis
November 11, 2014 at 16:03 PM EST
Amgen (NASDAQ: AMGN) and AstraZeneca (NYSE: AZN) today announced that AMAGINE-3(TM) , a pivotal, multi-arm Phase 3 trial evaluating ...